Are dry eye patients with low omega-3 index the beneficiaries of omega-3 fatty acids supplements?

Omega-3 fatty acids and tear cytokine modulation in dry eye patients with low omega-3 index. Have the beneficiaries been pinpointed? - Omega-3 fatty acids and tear cytokine modulation in dry eye patients with low omega-3 index. Have the beneficiaries been pinpointed?

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059836

Enrollment

100

Registered

2025-11-20

Start date

2025-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

Four capsules each containing 325 mg of EPA and 175 mg of DHA, totalling 1300 mg of EPA and 700 mg of DHA per day for 6 months. Olive oil capsules comprising 70% oleic acid, 18% linoleic acid, and 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic dry eye patients with omega-3 index less than 4%

Exclusion criteria

Exclusion criteria: Current ocular infection recent refractive surgery allergic conjunctivitis contact lens use herpetic eye disease diabetes liver diseases inability to swallow soft gel capsules, aspirin or anti-coagulant therapy allergy to fluorescein

Design outcomes

Primary

Measure	Time frame
Cytokines Tears Conjunctiva Computer users	—

Secondary

Measure	Time frame
Schirmer TBUT Goblet cells Symptoms	—

Countries

Asia(except Japan)

Contacts

Public ContactPrachi Kumar

Yashodha Medicity Ghaziabad

kumarprachi@yahoo.co.in+918076020248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026